B · Normal
On November 4th, Novo Nordisk’s adjusted sales of Wegovy oral drug in the third quarter were 5.39 billion Danish kroner, compared with the expected 4.64 billion Danish kroner.
Related telegraphs
November 4th, Novo Nordisk expects Wegovy oral medicine to be launched in more t
11-04 14:48
November 4th, Novo Nordisk expects the adjusted sales growth rate at constant ex
11-04 14:33
On October 20, Novo Nordisk said that its new generation weight loss drug CagriS
10-20 21:58
On October 16th, Eli Lilly said that its oral weight loss drug Foundayo has been
10-16 18:01
On October 7, the U.S. healthcare sector bucked the trend and rose early in the
10-07 21:52
On September 30, Eli Lilly announced the research data of Eloratzp (a combinatio
09-30 22:17
Comments